

## FUTURE PLANS AND [REDACTED]

### FUTURE PLANS

For details of our future plans, see “Business—Our Strategies.”

#### [REDACTED]

We estimate that we will receive net [REDACTED] of approximately HK\$[REDACTED] after deducting the [REDACTED] fees and expenses payable by us in the [REDACTED], assuming no exercise of the [REDACTED] and assuming an [REDACTED] of HK\$[REDACTED] per [REDACTED], being the [REDACTED] of the indicative [REDACTED] range of HK\$[REDACTED] to HK\$[REDACTED] per [REDACTED] set forth in this document. We intend to use the net [REDACTED] from the [REDACTED] for the following purposes:

- Approximately HK\$[REDACTED] (representing [REDACTED] of the estimated net [REDACTED]) will be used for the research and development of therapeutic and access products for hemorrhagic stroke, cerebral atherosclerotic stenosis and AIS:
  - Approximately HK\$[REDACTED] (representing [REDACTED] of the net [REDACTED]) will be used to offer total solutions for hemorrhagic stroke. Specifically, we will (i) develop upgraded generations of *NUMEN*, including *NUMEN NEST* and *NUMEN Biodegradable*; (ii) develop *Tubridge*’s next-generation product, *Tubridge Plus*, which is now in the design validation stage; and (iii) move forward with the clinical trials and registration approval process of *Rebridge*;
  - Approximately HK\$[REDACTED] (representing [REDACTED] of the net [REDACTED]) will be used to fund the research and development of cerebral atherosclerotic stenosis products, including (i) preclinical studies, clinical trial and commercialization of large-size *Bridge (Bridge 4.5/5.0)*; and (ii) any refinement as may be required for *Diveer Intracranial Balloon Dilatation Catheter* towards its registration approval;
  - Approximately HK\$[REDACTED] (representing [REDACTED] of the net [REDACTED]) will be used for research and development of AIS products to establish a comprehensive portfolio. Specifically, we will (i) develop *Neurohawk*’s next-generation, *Neurohawk 2*, with wider applicability in procedures; and (ii) increase investments in the development of aspiration catheters, balloon guiding catheters and distal access technology;
- Approximately HK\$[REDACTED] (representing [REDACTED] of the estimated net [REDACTED]) will be used for the commercialization of our products for hemorrhagic stroke, cerebral atherosclerotic stenosis and AIS:
  - Approximately HK\$[REDACTED] (representing [REDACTED] of the net [REDACTED]) will be used for the expansion of our sales and marketing team to accommodate our continuous product commercialization and regional expansion. Specifically, we plan to expand team members in our Eagle & Swallows (神雕飛燕) program to promote our products in lower-tier cities and counties;
  - Approximately HK\$[REDACTED] (representing [REDACTED] of the net [REDACTED]) will be used for sales and marketing activities to enhance our brand awareness and

## FUTURE PLANS AND [REDACTED]

promote our new products. Specifically, we intend to (i) increase our presence in academic conferences to enhance our brand awareness; (ii) introduce our new products to key opinion leaders to enhance product recognition; and (iii) provide training sessions to physicians for them to familiarize with our new products and practice patterns;

- Approximately HK\$[REDACTED] (representing [REDACTED] of the estimated net [REDACTED]) will be used for the expansion of our manufacturing facility to increase the scale of our production, including:
  - Approximately HK\$[REDACTED] (representing [REDACTED] of the net [REDACTED]) will be used for the construction of a manufacturing facility with an aggregate GFA of approximately 7,000 sq.m. in accordance with GMP standards in Zhangjiang, Shanghai, to increase our production capacity to approximately 350,000 units per year in 2025;
  - Approximately HK\$[REDACTED] (representing [REDACTED] of the net [REDACTED]) will be used for establishing an overseas R&D and production center in Irvine, California, the United States;
- Approximately HK\$[REDACTED] (representing [REDACTED] of the estimated net [REDACTED]) will be used for the expansion of our global presence;
  - Approximately HK\$[REDACTED] (representing [REDACTED] of the net [REDACTED]) will be used advancing the research and development, registration approval and commercialization of our products in overseas market;
  - Approximately HK\$[REDACTED] (representing [REDACTED] of the net [REDACTED]) will be used for establishing our international sales and marketing team to cover the Americas, Europe, the Middle East and Africa and expanding our sales and marketing team in Asia Pacific;
- Approximately HK\$[REDACTED] (representing [REDACTED] of the estimated net [REDACTED]) will be used for advancing our product portfolio through strategic acquisitions, investment, cooperation or a combination of these tactics. As of the Latest Practicable Date, we had not identified any investment or acquisition target; and
- Approximately HK\$[REDACTED] (representing [REDACTED] of the net [REDACTED]) will be used for working capital and other general corporate purposes.

The above allocation of the [REDACTED] will be adjusted on a pro rata basis in the event that the [REDACTED] is fixed at a higher or lower level compared to the mid-point of the estimated [REDACTED] range. If the [REDACTED] is set at HK\$[REDACTED] per [REDACTED], being the high end of the indicative [REDACTED] range, the net [REDACTED] from the [REDACTED] will increase by approximately HK\$[REDACTED]. If the [REDACTED] is set at HK\$[REDACTED] per [REDACTED], being the low end of the indicative [REDACTED] range, the net [REDACTED] from the [REDACTED] will decrease by approximately HK\$[REDACTED].

If the [REDACTED] is exercised in full, and net [REDACTED] that we will receive will be approximately HK\$[REDACTED], assuming an [REDACTED] of HK\$[REDACTED] per [REDACTED] (being

## FUTURE PLANS AND [REDACTED]

---

the mid-point of the indicative [REDACTED] range). In the event that the [REDACTED] is exercised in full, we intend to apply the additional net [REDACTED] to the above purpose in the proportions stated above.

To the extent that the net [REDACTED] are not immediately applied to the above purposes and to the extent permitted by the relevant law and regulations, so long as it is deemed to be in the best interests of the Company, we may hold such funds in short-term deposits with licensed banks or authorized financial institutions. We will make an appropriate announcement if there is any change to the above proposed [REDACTED].